The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.
 
Sarah B. Goldberg
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Genzyme; Janssen; Merck; Mirati Therapeutics; Regeneron; Summit Therapeutics; Takeda
Research Funding - Amgen (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Mirati Therapeutics; Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
 
Salman Rafi Punekar
Research Funding - Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
 
Vamsidhar Velcheti
Honoraria - ITeos Therapeutics
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Elevation Oncology; GlaxoSmithKline; Merck; Merus; Taiho Oncology
Research Funding - Alkermes (Inst); Altor BioScience (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech (Inst); Genoptix (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Leap Therapeutics (Inst); Merck (Inst); NantWorks (Inst); OncoPlex Diagnostics (Inst); RSIP Vision (Inst); Trovagene (Inst)
 
Jonathan W. Riess
Consulting or Advisory Role - Bayer; BeiGene; Biodesix; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; EMD Serono; Genentech; Janssen Oncology; Jazz Pharmaceuticals; Merus NV; Novartis; Regeneron; Sanofi; Seagen; Summit pharmaceuticals; Turning Point Therapeutics
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Merck (Inst); Novartis (Inst); Revolution Medicines (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Katherine Ann Scilla
No Relationships to Disclose
 
Jennifer W Carlisle
Research Funding - AstraZeneca (Inst)
 
Katerina A. Politi
Consulting or Advisory Role - AstraZeneca; Halda Therapeutics; Janssen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); D2G Oncology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent licensed by MSKCC to Molecular MD for T790M testing
Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Lung Cancer Research Foundation
 
Jong Woo Lee
No Relationships to Disclose
 
Thomas J. Myers
Employment - VITRAC Therapeutics
Leadership - VITRAC Therapeutics
Stock and Other Ownership Interests - VITRAC Therapeutics
 
Linda J. Paradiso
Employment - VITRAC Therapeutics
Leadership - VITRAC Therapeutics
Stock and Other Ownership Interests - Amgen; Pfizer; VITRAC Therapeutics
 
Barbara Burtness
Consulting or Advisory Role - Abbvie; ALX Oncology; Arvinas; Coherus Biosciences; CUE Biopharma; Genentech/Roche; IO Biotech; Kura Oncology; Macrogenics; Merck; Merck KGaA; Vaccinex
Speakers' Bureau - Clinical Education Alliance; Oncology Education
Research Funding - CUE Biopharma (Inst); Exelixis (Inst); Merck; Merck (Inst)